TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.340nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.340nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.410nMAssay Description:Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.520nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.520nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.540nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.540nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.590nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.590nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.600nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.600nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.660nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.660nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.670nMAssay Description:Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.690nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.690nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.710nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.850nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.850nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.860nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.860nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.910nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.910nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.920nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.920nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.980nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.980nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 0.990nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1nMAssay Description:Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.10nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.10nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.20nMAssay Description:Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.30nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.40nMAssay Description:Displacement of [3H]-citalopram from human SERT expressed in HEK293 cell membranes after 60 mins by liquid scintillation countingMore data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.5nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Dainippon Pharma
US Patent
Sumitomo Dainippon Pharma
US Patent
Affinity DataKi: 1.60nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair